нВ, MD,‡ Daren M. Beam, MD,#


Michael W. Ardagh, MB, ChB, DCh, PhD,† Richard Troughton, MB, ChB, PhD,\*† Anthony F. T. Brown, MB, ChB,‡ Peter George, MB, BS,\* Christopher M. Florkowski, MB, BS,\* Jeffrey A. Kline, MD,# W. Frank Peacock, MD,\*\* Alan S. Maisel, MD,†† Swee Han Lim, MB, BS,‡‡ Arvin Lamanna, MB, BS,‡ A. Mark Richards, MD, PhD†

Christchurch, New Zealand; Brisbane and Melbourne, Australia; Charlotte, North Carolina; Cleveland, Ohio, San Diego, California; and Singapore


**Objectives** 

 $M \ e \ t \ h \ o \ d \ s$ 









The results show that the ADP is sensitive for both early and late presenters, identifying a greater proportion of patients as low risk in early presenters. Thus, the ADP could have the greatest impact in patients presenting within 3 h of symptom onset, the group in which the second troponin sampling time point is usually most delayed.

Body et al. (21) described how a highly sensitive cTn (HS-cTn) assay may allow early "rule-out" of AMI using a